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Active ingredients are reported more often for
pharmacologic than non-pharmacologic
interventions: an illustrative review of reporting
practices in titles and abstracts
Nicola McCleary1*, Eilidh M Duncan2, Fiona Stewart3 and Jill J Francis4
Abstract
Key components of healthcare interventions include ‘active ingredients’ (intervention components that can be
specifically linked to effects on outcomes such that, were they omitted, the intervention would be ineffective).
These should be reported in titles and abstracts of published reports of randomized controlled trials (RCTs).
However, reporting of non-pharmacologic interventions (NPIs), particularly behaviour change interventions (BCIs), is
difficult, owing to their complexity. This illustrative review compares how pharmacologic interventions (PIs), NPIs
and BCIs are specified in titles and abstracts to clarify how reporting of NPIs and BCIs can be improved. MEDLINE
and Embase were searched for RCTs published in the British Medical Journal, The Journal of the American Medical
Association, The New England Journal of Medicine, The Lancet and Annals of Behavioral Medicine from 2009 to March
2011. All types of intervention, participant and outcome were included. A random sample of 198 studies (sampled
proportionally from included journals) stratified by intervention type (PI/NPI) was taken: 98 evaluated PIs, 96
evaluated NPIs and four evaluated both. Studies were coded for the presence or absence of key components. The
frequency data were analyzed using the chi-square test. Active ingredients were named in 88% titles and 95%
abstracts of PI reports, and in 51% titles and 71% abstracts of NPI reports, with a significant association between
intervention type and reporting of active ingredients in titles (χ2(1) = 28.90; P < 0.001) and abstracts (χ2(1) = 16.94; P
< 0.001). Active ingredients were named in BCI reports in 37% titles and 56% abstracts, and in other NPI reports in
66% titles and 86% abstracts. There was also a significant association between intervention type and reporting of
active ingredients in titles (χ2(1) = 6.68; P = 0.010) and abstracts (χ2(1) = 8.66; P = 0.003). Reporting practices also
differed for such components as the trial setting and intervention provider. This review highlights the need for
improved reporting of NPIs (particularly BCIs) and indicates that a set of agreed labels and definitions for complex
NPIs could facilitate standardized reporting. This would ensure that interventions can be faithfully replicated and
that evidence for interventions can be appropriately synthesized.
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Background
Well designed and executed randomized controlled trials
(RCTs) are the gold standard for assessing intervention
efficacy and effectiveness, but study synthesis, compari-
son and reproducibility are compromised if interven-
tions are poorly reported [1,2]. Articles should contain
details of key study components (Table 1) including
‘active ingredients’ [1,3]. The term ‘active ingredient’ is
frequently used to refer to the element within a pharma-
cologic intervention (PI) that is responsible for its thera-
peutic action. In contrast with PIs, non-pharmacologic
interventions (NPIs) are usually complex, containing
several interacting components that are all necessary for
the intervention to be effective [4]. Such interventions
may [5]:
 Involve several interacting components.
 Require many different behaviours from healthcare
professionals or participants for successful delivery.
 Be aimed at different levels within an organization.
 Have many different types of outcome
measurement.
 Be tailored to different contexts or settings within
one study.
The term ‘active ingredient’ was adopted in the UK
complex intervention literature because early guidelines
for the evaluation of complex interventions were based
on the phases used to evaluate PIs [6]. The term ‘active
ingredient’ refers to the components within an interven-
tion that can be specifically linked to its effect on out-
comes such that, if they were omitted, the intervention
would be ineffective. For example, a cardiac rehabilita-
tion intervention aimed at improving health-related be-
haviour associated with heart disease might focus on
supporting smoking cessation, regular physical activity
and a healthy diet [7]. Specific techniques used might in-
clude goal setting, providing information on conse-
quences of behaviour and prompting self-monitoring of
behaviour [8]. Provided these techniques have the poten-
tial to influence the health-related behaviour associated
with heart disease (that is, causally influence outcomes)
[7], they can be described as active ingredients. There-
fore, throughout this article, the term ‘active ingredients’
is used to refer to these components in both PIs and
NPIs. It is important to note that this is distinct from
the mechanisms of action of interventions (the under-
lying reasons why the active ingredients have their
particular effects) [7].
Accurate and comprehensive reporting of these com-
ponents in titles and abstracts is essential [1,9]. Abstracts
are more widely circulated than full-text articles [10]
and are generally the most widely available parts of arti-
cles [11]. Consequently, their content can have a greater
than anticipated impact [9]. Inadequate specification of
key components in titles and abstracts can have serious
Table 1 Checklists adapted from the CONSORT extension for abstracts [1] and the CONSORT extension for
non-pharmacologic interventions [2]
Section of paper Component to be
reported
Details to be reported
Title Randomization Specify the use of randomization
Abstract Study design Description of trial design
Participants Eligibility criteria and data collection setting
Interventions Interventions given to each group within the trial
Objective Objective or hypothesis of the trial
Primary outcome Specification of the primary outcome, result for each intervention group, estimated
effect size and precision
Randomization Method used to allocate participants to intervention groups
Blinding Who was blinded to group assignment
Numbers randomized and
analyzed
Number of participants randomized to and analyzed in each intervention group
Recruitment Specify whether study is ongoing, closed to recruitment, or closed to follow-up
Harms Significant adverse events or side effects that occurred
Conclusions Evaluation of the results
Trial registration Trial register name and registration number
Funding Funding source
Abstract (non-pharmacologic
interventions)
Full description of the experimental treatment; comparator; care providers administering intervention; centres
within which intervention administered; trial blinding status
CONSORT, Consolidated Standards of Reporting Trials.
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implications for systematic reviews, which are consid-
ered the best sources of evidence about the effectiveness
of interventions [12]. Since reviewers base their initial
inclusion decisions on abstracts [9], inadequate specifi-
cation may result in studies being inappropriately
rejected from the review, thus compromising review val-
idity. Additionally, many readers use abstract content to
determine whether full-text retrieval is worthwhile
[1,11,13], while in certain countries, many healthcare
professionals have easy access to abstracts but not to full
texts [1,9]. Therefore, it is important to investigate the
quality of reporting in RCT abstracts.
The Consolidated Standards of Reporting Trials (CON-
SORT) guidelines [14] were developed to improve the
quality of reporting of RCTs, and specific CONSORT
guidelines (Table 1) have been developed for abstracts [1]
and for NPIs [2], including surgical interventions, devices,
rehabilitation packages and behaviour change interven-
tions (BCIs) [15]. Owing to their complexity, NPIs are
typically more difficult to standardize, describe and
administer consistently than PIs while intervention
success is often dependent on the expertise of the inter-
vention providers [2,15].
It is plausible that PIs may be reported more precisely
than NPIs in titles and abstracts, owing to the complex-
ity of NPIs and the restrictive word limits of titles and
abstracts. The active ingredients of a PI can usually be
specified clearly in one phrase within a sentence (for
example, ‘Zoledronic acid’ [16]). However, an NPI often
cannot be specified so succinctly: as a result, interven-
tion objectives are often specified, while active ingredients
are often not reported (for example, ‘Self-management
programme. The programme teaches patients medical, so-
cial and emotional self-management skills.’ [17]). Compar-
isons of full-text articles have found that PIs are more
often described with enough detail to be faithfully
reproduced [18], and that descriptions of the key compo-
nents of NPIs are reported less often and less precisely
than those of PIs [19]. However, we are not aware of any
reviews that have systematically evaluated the reporting of
NPIs as compared with PIs in titles and abstracts.
Given the importance of accurate intervention reporting
in titles and abstracts, an explicit comparison of reporting
practices for PIs and NPIs would be useful for a number
of reasons. Firstly, to establish whether there are similar
disparities in the quality of abstract reporting between PIs
and NPIs as there are for full-text articles. Reviews of full-
text articles have illustrated how reporting of NPIs can be
improved based on PI reporting practices; a comparative
review of abstracts could similarly illustrate how the
reporting of abstracts describing NPIs could be improved.
Title and abstract reporting practices for BCIs, a sub-
set of NPIs that aim to modify health-related behaviour
[20,21], require special scrutiny. The CONSORT reporting
guidelines have been adopted by most behavioural
research journals [22]. Although Davidson and colleagues
[3] proposed additional guidelines for reporting BCIs,
these do not include specific recommendations for
abstracts. It has been argued that full-text reports of BCIs
usually do not fully comply with these guidelines [22].
However, to our knowledge, title and abstract reporting
practices for BCIs have not been reviewed systematically.
These issues highlight that an explicit comparison of
title and abstract reporting practices of PIs, NPIs and
BCIs is necessary to clarify how reporting of NPIs and
BCIs can be improved. This illustrative review compares
the specification of interventions in titles and abstracts
of published reports of RCTs. It was hypothesized that
active ingredients would be reported more often for PIs
than NPIs, and for other NPIs than BCIs.
Methods
Data sources and search methods
Studies were sampled from the British Medical Journal,
The Journal of the American Medical Association, The
New England Journal of Medicine, The Lancet and
Annals of Behavioral Medicine (ABM). The first four
journals each have a high impact factor [23], which is as-
sociated with high methodological quality of articles
[24]. These journals consequently provide a source of
high-quality reports. ABM is the most influential behav-
ioural research journal (with an impact factor in 2010 of
3.984) and is assumed to exemplify high-quality
reporting of BCIs. This journal was selected so that an
adequate sample of high-quality BCI reports could be in-
cluded. This choice of a limited range of journals is in
accordance with previous comparisons of reporting prac-
tices where the goal is not to be exhaustive but to high-
light the issues inherent in the reporting of NPIs [18].
A search strategy (Additional file 1) comprising both
Medical Subject Headings and text words was designed
and executed in MEDLINE (1946 to March 2011 Week
3) and Embase (1980 to 2011 Week 11), using the Ovid
interface. The search strategy identified RCTs and spe-
cific journal titles, imposed a date restriction to reflect
recent reporting practice (January 2009 to March 2011)
and used the controlled vocabulary term ‘drug therapy’
to distinguish between PI and NPI reports.
Inclusion criteria
Only RCTs or randomized studies were considered for
inclusion. Eligible interventions were PIs or NPIs. Eli-
gible comparator interventions were control treatments
or other PIs or NPIs. There were no restrictions on the
types of participant, outcome measure or length of
follow-up. Papers that were not the primary report of a
study (for example secondary analyses of trial data) were
excluded. CONSORT recommends that although space
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limitations restrict abstract content, interventions should
be described with enough detail to be fully understood
[1]. This should be the objective of primary research re-
ports. Intervention description is not necessarily the
main focus of secondary research reports, and so a full
description of the intervention may legitimately be omit-
ted from the title or abstract.
Study selection and data extraction
One researcher (NM) conducted the search and ran-
domly selected 210 papers (10 for piloting the method
and 200 for the main analysis) [25]. Since this review ex-
plored differences in reporting practices, the inclusion of
210 papers was judged to be representative of reporting
variations in high-quality journals. Additionally, this
number of papers would be unlikely to violate the statis-
tical assumptions of the proposed chi-square analyses.
To ensure that the sample was representative of the
population of studies considered, papers were sampled
proportionally to reflect the proportions of PI and NPI
reports typically published by these journals, rather than
sampling an equal number of papers from each journal.
The calculations performed to determine the numbers
of PI and NPI reports to be sampled from each journal
are included in Additional file 2. One researcher (NM)
screened all titles and abstracts to determine eligibility.
Any uncertainties were resolved through discussion with
the research team.
A data extraction form (Additional file 3) was devel-
oped by one researcher (NM), in collaboration with the
research team, using the Cochrane Handbook for System-
atic Reviews of Interventions [26]. The form contained a
classification scheme, used to extract details of interven-
tion components, created using CONSORT guidelines.
The form was piloted by one researcher (NM) and a col-
league (a trainee health psychologist). Data extracted in
relation to components reported were converted into
frequency data, and inter-coder agreement was assessed
for each of the ten pilot papers using the Kappa statistic.
Kappa values ranged between 0.44 and 0.76, indicating
moderate or substantial agreement for all ten papers
[27]. Minor changes were made to the form following
piloting. Piloting indicated that the classification scheme
could be used to extract relevant data from titles and ab-
stracts and that the scheme was fully comprehensive in
terms of the components of interventions typically
reported in titles and abstracts. Data extraction was car-
ried out by one researcher (NM) and any uncertainties
were resolved through discussion with the research team.
Data analysis
The studies were coded for the presence or absence of
study components, resulting in frequency data that were
analyzed using SPSS version 17.0. We recognized that
coding the presence or absence of active ingredients of
NPIs might be a matter of personal judgement, and so
two authors (JJF and NM), independently coded the
presence or absence of active ingredients for all NPI
titles. JJF was blinded to the original coding, while NM
re-coded these titles without reviewing the original cod-
ing. Discrepancies were agreed by consensus. This
ensured consistency between our definition of active in-
gredients and the resultant coding.
Chi-square tests were performed for titles and abstracts
separately to investigate the associations between interven-
tion type (PI/NPI) and reporting of the intervention’s active
ingredients (yes/no). This was repeated to compare BCIs
with other NPIs, which was a pre-specified subgroup ana-
lysis. Exploratory chi-square analyses illustrating further
differences in reporting practices were also conducted.
Results
Study selection
The search identified 1,250 papers after deduplication,
from which the random sample of 210 was taken. After
removal of the ten papers used for piloting, one dupli-
cate and one non-primary RCT report, 198 papers were
reviewed, of which 98 were PI reports and 96 were NPI
reports. Four papers reported both intervention types
and were not included in the analyses. Details of the
search are summarized in Figure 1.
Characteristics of included studies
Of the 98 PI reports, 87 evaluated a drug, 10 evaluated a
vaccine and one evaluated both a drug and a vaccine. The
interventions described within the 96 NPI reports were
categorized as either behaviour change (when aimed at
changing behaviour; 41 reports); surgery (10 reports);
device (9 reports); screening (5 reports); food supplemen-
tation (involving a preparation aimed at supplementing
diet; 5 reports); or rehabilitation (when aimed at restoring
health and/or functioning; 5 reports). These categories
were created based on the studies used in the piloting
phase.
An intervention type could not be specified for five
papers (these were excluded from all subgroup analyses
as it was unclear whether or not they were BCIs). The
remaining 16 papers reported evaluations of interven-
tions that could not be classified into any of the six cat-
egories mentioned previously (see Additional file 4). Five
papers that reported more than one trial were excluded
from all analyses as a full intervention description might
not have been provided. The basic characteristics of in-
cluded studies are presented in Additional file 4.
Analysis of included studies
Table 2 illustrates intervention component coding. Figures 2
and 3 show the percentages of PI and NPI titles and
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abstracts reporting specific intervention components. In ti-
tles, PI articles more often reported the active ingredients,
comparator interventions, eligibility criteria and blinding
status; NPI articles more often reported the setting and
intervention objectives (Figure 2). In abstracts, PI articles
more often reported the active ingredients, dose or inten-
sity, method of administration, frequency of treatment, dur-
ation of treatment and blinding status; NPI articles more
often included the settings, intervention objectives and
intervention providers (Figure 3).
Active ingredients were named in the majority of titles
(82/93, 88.17%) and abstracts (88/93, 94.62%) of PI re-
ports, but less frequently in the titles (49/96, 51.04%)
and abstracts (68/96, 70.83%) of NPI reports. There was
a significant association between intervention type and
reporting of the active ingredients for titles (χ2(1) =
28.90; P < 0.001) and abstracts (χ2(1) = 16.94; P < 0.001).
BCI reports named active ingredients in just over a
third of titles (15/41, 36.59%) and just over half of ab-
stracts (23/41, 56.10%). Reports of other NPIs named ac-
tive ingredients in two-thirds of the titles (33/50,
66.00%) and in the majority of abstracts (43/50, 86.00%).
There was a significant association between NPI inter-
vention type and reporting of the active ingredients for
titles (χ2(1) = 6.68; P = 0.010) and for abstracts (χ2(1) =
8.66; P = 0.003). We discovered that while ABM limits
abstracts to 150 words [30], the abstract limits of the
other included journals range between 250 and 300
words [31-34]. Consequently, we conducted a sensitivity
analysis by removing the six papers published in ABM
but we still found a significant association between NPI
intervention type and reporting of the active ingredients
for titles (χ2(1) = 5.79; P = 0.016), and abstracts (χ2(1) =
10.50; P = 0.001).
1454 records identified by database 
search
1250 records remain after 
duplicates removed: random sample 
of 210 to be taken: 470 titles and 
abstracts screened
204 duplicates removed
260 excluded (non-RCTs)
210 selected for inclusion (104 
reports of PIs, 106 reports of NPIs)
198 included in review (98 reports 
of PIs, 96 reports of NPIs, 4 
reporting both a pharmacologic 
intervention and a non -
pharmacologic intervention)
2 excluded (1 non-primary 
RCT report, 1 duplicate )
10 used for piloting
Figure 1 Flow chart of identification and selection of included studies. NPI = non-pharmacologic intervention; PI = pharmacologic intervention;
RCT = randomised controlled trial.
Table 2 Example of study component coding
Pharmacologic intervention title: ‘Vitamins C and E for
prevention of pre-eclampsia in women with type 1 diabetes
(DAPIT): a randomized placebo-controlled trial’ [28]
Non-pharmacologic intervention title: ‘Treatment of
childhood obesity by retraining eating behaviour:
randomized controlled trial’ [29]
Active ingredients Vitamins C and E Not reported
Comparator Placebo Not reported
Health condition Pre-eclampsia Obesity
Eligibility criteria Women with type 1 diabetes Children
Objective Prevention of pre-eclampsia Retraining eating behaviour
Trial design Randomized controlled trial Randomized controlled trial
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We conducted exploratory analyses to investigate
whether intervention objectives or settings might be
reported in place of active ingredients, as is sometimes the
case for NPIs (for example, describing an intervention as
‘a weight-loss intervention’ rather than as a ‘cognitive be-
havioural therapy intervention to support weight loss’).
The majority of PI articles reporting an objective in the
title also reported the active ingredients (16/26, 61.54%)
and similarly for abstracts (44/48, 91.67%). However, ap-
proximately a third of NPI articles reporting an objective
in the title also reported the active ingredients (19/59,
32.20%) while nearly two-thirds did so in abstracts (40/64,
62.50%). There was a significant association between
intervention type and reporting of active ingredients with
objectives for titles (χ2(1) = 5.26; P = 0.022) and abstracts
(χ2(1) = 10.94; P = 0.001).
The trial setting was reported in the titles of two PI re-
ports and 15 NPI reports, 11 of which did not report ac-
tive ingredients. The vast majority of PI articles reporting
the setting in the abstract also reported the active ingredi-
ents (36/38, 94.74%), whereas nearly two-thirds of the NPI
articles reporting the setting in the abstract did so (36/57,
63.16%). There was a significant association between
intervention type and reporting of active ingredients with
Figure 2 Percentage of titles reporting specific study components. NPI = non-pharmacologic intervention; PI = pharmacologic intervention.
* Statistical significance of differences in percentages of studies were tested for the ‘active ingredients’ component only: P< 0.001. Note: All other
study components reported by <10% of either the PI or NPI reports so are not included in figure (primary outcome; dose/intensity; frequency of
treatment; duration of treatment; comparator dose/ intensity; comparator method of administration; comparator frequency of treatment;
comparator duration of treatment; timing of outcome assessment; trial phase; trial registration; intervention providers).
Figure 3 Percentage of abstracts reporting specific study components. NPI = non-pharmacologic intervention; PI = pharmacologic
intervention. * Statistical significance of differences in percentages of studies were tested for the ‘active ingredients’ component only: P< 0.001.
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settings for abstracts (χ2(1) = 10.73; P= 0.001). In sum-
mary, it appears that when intervention objectives and set-
tings are reported for NPIs, active ingredients are often
missing.
In the abstracts, details of the intervention providers
were reported for three PIs and 18 NPIs. The three PI
articles reported the involvement of healthcare profes-
sionals. Fourteen of the 18 NPI abstracts reported who
provided the intervention, while four (which were all
reports of BCIs) provided additional information on the
training delivered.
Discussion
Active ingredients were reported significantly less often
in titles and abstracts for NPIs than PIs, and for BCIs
than other types of NPIs. These results are in accor-
dance with those described previously from reviews
comparing full-text PI and NPI reports [18,19]. This in-
dicates that improvements are required in the reporting
of NPIs in titles and abstracts, and that, in accord with
much of the literature [35], titles and abstracts of BCI
reports in particular lack a detailed intervention descrip-
tion. Without this key information, readers are left with
an incomplete picture of what the intervention involved
[14]. On the basis of our findings, we recommend that
all authors routinely report active ingredients in titles
and abstracts, and that all journal editors routinely re-
quire this.
It is possible that variation in reporting is attributable
to the differences in the existing nomenclature for these
interventions. Agreed labels (drug names) are used for
the same PI [18,36], making specification more straight-
forward. NPIs, however, usually involve procedures that
can be labelled and performed in a variety of ways
[2,19], as illustrated in Table 3. Here, the same term is
used to label the interventions in the title, but very dif-
ferent descriptions are provided in the articles. A set of
agreed labels and definitions of active ingredients of
complex interventions, which is currently lacking [36],
would help to standardize reporting. Indeed, a system
for specifying the exact techniques used in BCIs has re-
cently been developed [21].
Furthermore, abstract space limitations might con-
tribute to these reporting differences. The CONSORT
guidelines for abstracts state that 250 to 300 words
are sufficient to report all recommended items [1].
However, it is likely that specifying PIs requires fewer
words than NPIs. Another study of abstract reporting
quality found that a greater abstract word count was
associated with higher reporting quality for structured
abstracts [13]. The 150-word limit for abstracts im-
posed by ABM therefore seems unsuitable. Journals
could consider increasing abstract word limits to fa-
cilitate higher-quality abstract reporting, particularly
for NPIs.
The exploratory analyses suggested that when inter-
vention objectives and settings are reported for NPIs, ac-
tive ingredients are often missing. This concurs
particularly with previous behavioural research, where
greater focus is often placed on reporting such aspects
as the intervention objectives, trial setting, method of
administration and intervention providers [3,8]. Al-
though these are important, describing interventions in
this way can make different intervention content indis-
tinguishable and thus make it difficult to determine the
specific techniques that might be critical to intervention
effectiveness [8].
Only 59% of the NPI reports mentioned the setting
in the abstract. This seems low, given that the set-
tings in which NPIs are administered are likely to
interact with the intervention’s active ingredients to
influence its effectiveness [40]. In addition, the effect-
iveness of an NPI can be influenced by the skills, ex-
perience and enthusiasm of the providers [18]. The
CONSORT guidance for NPIs states that the number
of providers involved in intervention delivery and de-
tails of their expertise should be reported in the ab-
stract [2]. However, only 19% of the NPI reports
contained any information about intervention pro-
viders in the abstract. Clearly, reporting of these com-
ponents also requires improvement.
This is the first review to compare reporting of specific
components of PIs and NPIs in titles and abstracts, and
is therefore the first to show that active ingredients are
reported more often in titles and abstracts for PIs than
NPIs. There are, however, important limitations of this
work. It was assumed that all included studies were of a
high quality because they were published in high-impact
journals: this cannot be confirmed, since a full quality
assessment was not conducted. This was beyond the
scope of this project. Our findings may be generalizable
to other general medical journals of similar quality; how-
ever, the generalizability of our findings to other types of
journal or conference abstracts may be limited. Journal
recommendations for abstract word length were not
verified at the outset of the study, and so there was
Table 3 Different descriptions of ‘behavioural
counselling’ intervention in two studies (adapted
from [37])
Study 1 [38] Study 2 [39]
Feedback (on diaries) Assessment of readiness to change
Reinforcement Attitude change
Recommendations for change Goal setting
Answers to questions Specific behavioural advice
General support
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imbalance between the journals targeted. Abstract limits
were not checked because, as specified previously, our
criterion for journal selection was high journal quality.
Data extraction and analysis were carried out by one re-
viewer. However, coding the active ingredients of NPIs
was conducted by two reviewers, and there was general
consensus regarding the data extracted during piloting.
Study dropout must also be highlighted; one duplicate,
one non-primary RCT report and four reports describing
both intervention types were removed from the analysis.
This resulted in unbalanced numbers of papers in the PI
and NPI categories; these excluded papers could have
been replaced, such that an equal number of papers in
each group were analyzed.
The many differences between PIs and NPIs might
make comparison difficult to interpret; however, existing
abstract reporting guidelines were designed to apply to
both intervention types, implying that both abstract types
should be written to a similar standard. We have shown
that this is not the case in these journals. Owing to the
proportional sampling strategy used, only six articles pub-
lished in ABM were included. The sample reflected the
relative frequency of publication: fewer RCTs are pub-
lished in ABM than in the other journals; therefore, fewer
were retrieved and sampled. Although this reflects the
relative frequency of publication, this is a limitation, given
that this journal was specifically selected for inclusion of
high-quality reports of BCIs.
One final important limitation concerns the link be-
tween abstract and full-text reporting. Reviews of full-
text articles [18,19] and reviews of abstracts [9,10,13,41]
have highlighted deficiencies in reporting. However,
more research is required to verify whether the quality
of abstract reporting is linked to that of full-text
reporting. It is therefore not clear whether findings simi-
lar to ours would be obtained if full-text articles were
reviewed in the same way: this is an important follow-up
evaluation.
This review has several strengths. No intervention types
were excluded, so the results apply broadly to reporting of
PIs and NPIs. Included studies were recently published in
high-impact peer-reviewed journals, so it appears that
there are problems with very recent reporting practice even
for high-quality reports. Finally, this review is unique in
that it comprises an explicit comparison of the reporting of
specific intervention components in titles and abstracts.
The study of abstract quality is a fairly recent development
[9], with most reviews focused on reporting of trial compo-
nents [9,10,13]. Many studies use the CONSORT abstract
reporting guidelines to evaluate quality. CONSORT speci-
fies that intervention details should be reported, but gives
no guidance on how they should be reported: this is the
first review of abstracts to focus specifically on the level of
detail provided regarding different types of intervention.
Conclusions
Active ingredients were more frequently reported in titles
and abstracts for PIs than for NPIs, and more frequently
for other NPIs than for BCIs. This review identifies the
need for improved reporting of NPIs, and BCIs in particu-
lar. The creation of agreed labels and definitions for active
ingredients of complex interventions, particularly BCIs,
would contribute towards clearer reporting.
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